Background: Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by bone erosions and new bone formation. MicroRNAs (miRNAs) are key regulators of the immune responses. Differential expression of miRNAs has been reported in several inflammatory autoimmune diseases; however, their role in PsA is not fully elucidated. We aimed to identify miRNA expression signatures associated with PsA and to investigate their potential implication in the disease pathogenesis.
Methods: miRNA microarray was performed in blood cells of PsA patients and healthy controls. miRNA pathway analyses were performed and the global miRNA profiling was combined with transcriptome data in PsA. Deregulation of selected miRNAs was validated by real-time PCR.
Results: We identified specific miRNA signatures associated with PsA patients with active disease. These miRNAs target pathways relevant in PsA, such as TNF, MAPK, and WNT signaling cascades. Network analysis revealed several miRNAs regulating highly connected genes within the PsA transcriptome. miR-126-3p was the most downregulated miRNA in active patients. Noteworthy, miR-126 overexpression induced a decreased expression of genes implicated in PsA.
Conclusions: This study sheds light on some epigenetic aspects of PsA identifying specific miRNAs, which may represent promising candidates as biomarkers and/or for the design of novel therapeutic strategies in PsA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937573 | PMC |
| http://dx.doi.org/10.1155/2018/7305380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glutaraldehyde functionalized reduced graphene oxide based resistive sensors for detection of PCA3.
J Mater Chem B
January 2025
Department of Electrical, Electronics and Communication Engineering, Indian Institute of Technology Dharwad, Karnataka - 580011, India.
Prostate cancer antigen 3 (PCA3) has emerged as a critical biomarker for the early detection of prostate cancer, complementing the traditional prostate-specific antigen (PSA) testing. This research presents a novel resistive sensor based on reduced graphene oxide (RGO) functionalized with glutaraldehyde (GA)/complementary single-stranded DNA (ss-DNA) for the detection of the PCA3 RNA. The device was meticulously characterized at each fabrication step to confirm the successful integration of the various layers on the sensor device, utilizing atomic force microscopy (AFM) which confirmed the increase in the thickness of the sensor from ∼1.
View Article and Find Full Text PDFUltrasound-guided Transperineal Prostate Thermal Ablation (TPTA) for Benign Prostatic Hyperplasia: Feasibility of an Outpatient Procedure using Radiofrequency Ablation.
Cardiovasc Intervent Radiol
January 2025
Department of Radiology, Universidade Federal de São Paulo (UNIFESP), Rua Dr. Ovidio Pires de Campos, 75, Cerqueira César, São Paulo, SP, 05403-010, Brazil.
Purpose: To evaluate the feasibility, safety, and short-term (3-month) results of transperineal prostate thermal ablation (TPTA) as a minimally invasive outpatient treatment for benign prostatic hyperplasia (BPH).
Materials And Methods: A prospective nonrandomized study of 25 patients with lower urinary tract symptoms secondary to BPH seeking care at 2 interventional radiology centers between March and July 2024. TPTA was performed using a 17G radiofrequency needle with a 10-mm active tip under unconscious sedation combined with bilateral perineal and periprostatic nerve blocks.
Using XBGoost, an interpretable machine learning model, for diagnosing prostate cancer in patients with PSA < 20 ng/ml based on the PSAMR indicator.
Sci Rep
January 2025
Department of Urology, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu, 241001, Anhui, People's Republic of China.
To create a diagnostic tool before biopsy for patients with prostate-specific antigen (PSA) levels < 20 ng/ml to minimize prostate biopsy-related discomfort and risks. Data from 655 patients who underwent transperineal prostate biopsy at the First Affiliated Hospital of Wannan Medical College from July 2021 to January 2023 were collected and analyzed. After applying the Synthetic Minority Over-sampling TEchnique class balancing on the training set, multiple machine learning models were constructed by using the Least Absolute Shrinkage and Selection Operator (LASSO) feature selection to identify the significant variables.
View Article and Find Full Text PDFAdult Embryonal Rhabdomyosarcoma of the Prostate Presented on 18F-FDG and Al18F-FAPI-74 PET/CT.
Clin Nucl Med
December 2024
From the Department of Nuclear Medicine (PET-CT Center), National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
A 21-year-old man with a 2-week history of abdominal pain and urinary hesitancy was admitted to our hospital. Sarcoma was suspected based on his PSA level, age, and MRI findings. He underwent 18F-FDG and Al18F-FAPI-74 PET/CT scans.
View Article and Find Full Text PDFContemporary prostate cancer radiation therapy trials may underestimate the risk of biochemical recurrence.
J Sex Med
December 2024
Sexual & Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
Background: Radiotherapy is often given with androgen deprivation therapy for prostate cancer which causes a reduction in testosterone levels, which when below castrate levels, can cause the prostate specific antigen (PSA) levels to be artificially low.
Aim: To determine if high-level radiotherapy clinical trials are underestimating biochemical recurrence (BCR) rates due to inadequate measurement of testosterone levels.
Methods: The study plans for clinical trials performed by the Radiation Therapy Oncology Group (RTOG [now NRG]) on clinicaltrials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!